|  |
| --- |
| Clinical Utility of Molecular Testing in  Follicular Lymphoma  Diagnostic Utility  The canonical moleular abnormality in classical follicular lymphoma (FL) is t(14;18)(q32;q21) resulting in the *IGH::BCL2* fusion gene and overexpression of *BCL2*1.  Four variants of FL are recognised in the WHO revised 4th edition classification: *in situ* follicular neoplasia (ISFN), duodenal-type FL, testicular FL and the diffuse variant of FL. In addition, paediatric-type FL is a separate entity1. ISFN and duodenal-type FL are characterised by t(14;18)(q32;q21) and share genetic features with classic FL2,3. *BCL2* translocations are not typically observed in the diffuse variant of FL or testicular FL1.  Del(1p) (which contains *TNFRSF14)*, acquired copy neutral loss of heterozygosity and mutations in *TNFRSF14* are commonly seen across all variants of FL including paediatric-type FL1. These findings are not detected by this assay.  *BCL2* aberrant somatic hypermutation is frequently observed in FL and germinal centre type diffuse large B cell lymphoma4,5.  Mutations in chromatin-modifying genes are recurrently observed in classic FL and typically occur as early events. These include *KMT2D* (~80%), *CREBBP* (~65%), *EZH2* (~25%), *ARID1A* (~15%) and *EP300* (~10%) mutations6-8.  Other recurrently mutated genes in classic FL include *STAT6*, *FOXO1*, *RRAGC*, *TNFAIP3*, *IRF8* and *CARD119-11*.  The finding of 1p36/*TNFRSF14* abnormalities along with *STAT6*, *CREBBP* and/or *KMT2D* mutations supports a diagnosis of a t(14;18)-negative FL12,13.  Primary WHO diagnostic criteria for paediatric-type FL include the absence of *BCL2*, *BCL6*, *IRF4* and aberrant immunoglobulin gene rearrangements as well as not having *BCL2* amplification1. Additionally, mutations in epigenetic modifiers frequently observed in classic FL are typically absent such as *KMT2D, CREBBP* and *EZH2*. Instead *MAP2K1* mutations are identified in approximately 50% of cases14. The *IRF8* Lys66Arg has been described as a recurrent mutation in paediatric type FL14,15.  Prognostic utility  The number of additional cytogenetic abnormalities, mutational burden and degree of aberrant somatic hypermutation (aSHM) increases at histological transformation1,16.  Histological transformation is associated with biallelic loss of *CDKN2A*/*CDKN2B* and/or *TP53*, *MYC* translocation and mutations in NFKB signalling (*MYD88, TNFAIP3)*1,6,16,17.  Biomarkers of response to therapy  Activating *EZH2* mutations are the target of the EZH2 inhibitor class of therapeutics18.  References  **1.** Swerdlow S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition). Lyon: IARC; 2017. **2.** Schmidt J, et al. CREBBP gene mutations are frequently detected in in situ follicular neoplasia. *Blood* 2018; **132**(25): 2687-90. **3.** Hellmuth JC, et al. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. *Blood* 2018; **132**(16): 1695-702. **4.** Burkhard R, et al. BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma. *Hematological Oncology* 2015; **33**(1): 23-30. **5.** Saito M, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. *Proc Natl Acad Sci U S A* 2009; **106**(27): 11294-9. **6.** Okosun J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. *Nat Genet* 2014; **46**(2): 176-81. **7.** Green MR. Chromatin modifying gene mutations in follicular lymphoma. *Blood* 2018; **131**(6): 595-604. **8.** Krysiak K, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. *Blood* 2017; **129**(4): 473-83. **9.** Pastore A, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. *Lancet Oncol* 2015; **16**(9): 1111-22. **10.** Yildiz M, et al. Activating STAT6 mutations in follicular lymphoma. *Blood* 2015; **125**(4): 668-79. **11.** Okosun J, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. *Nature Genetics* 2016; **48**(2): 183-8. **12.** Nann D, et al. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. *Blood Advances* 2020; **4**(22): 5652-65. **13.** Xian RR, et al. CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma. *Blood Cancer Journal* 2020; **10**(6): 69. **14.** Schmidt J, et al. Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. *Blood* 2017; **130**(3): 323-7. **15.** Ozawa MG, et al. A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. *Mod Pathol* 2016; **29**(10): 1212-20. **16.** Pasqualucci L, et al. Genetics of Follicular Lymphoma Transformation. *Cell Reports* 2014; **6**(1): 130-40. **17.** Correia C, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. *Blood* 2015; **125**(4): 658-67. **18.** Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. *Lancet Oncol* 2020; **21**(11): 1433-42. |